Impact Biomedical IBO
NYSE IBO
$0.48 +0.03 (+6.83%)
As of: Aug 21, 2026 · 2:19 PM EDT

Impact Biomedical (IBO) Free Cash Flow Growth (3y) (2025 - 2026)

Impact Biomedical (IBO) Free Cash Flow Growth (3y) (2025 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -1.95%
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -20.15%
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 21.16%
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 45.09%
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 80.69%
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -23.92%
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 8.92%
9 Royalty Pharma 27.27 Bn 26.43 Bn - -4.45%
10 Impact Biomedical 49.54 Mn 49.53 Mn 2,000.00 38.05%

Historic Data

Download Data
DateValue
Jun 30, 2026 38.05%
Mar 31, 2026 23.07%
Dec 31, 2025 31.48%
Sep 30, 2025 8.57%